Reported about 21 hours ago
Sanofi's third-quarter profits exceeded forecasts, driven by strong sales of its asthma drug Dupixent, although vaccine sales declined by 16.8% due to lower vaccination rates and negative perceptions surrounding vaccines. Despite the challenges in the vaccine market, overall sales in the U.S. rose by 11.1%. Sanofi reaffirmed its growth outlook for the year while acknowledging the difficulties posed by the current climate regarding vaccinations.
Source: YAHOO